List of bibliographic references
Number of relevant bibliographic references: 8.
| Ident. | Authors (with country if any) | Title |
|---|
| 001119 (2012) |
F. Tubach [France] ; P. Ravaud [France] ; E. Martin-Mola [Espagne] ; H. Awada [Liban] ; N. Bellamy [Australie] ; C. Bombardier [Canada] ; D. T. Felson [États-Unis] ; N. Hajjaj-Hassouni [Maroc] ; M. Hochberg [États-Unis] ; I. Logeart [France] ; M. Matucci-Cerinic [Italie] ; M. Van De Laar [Pays-Bas] ; D. Van Der Heijde [Pays-Bas] ; M. Dougados [France] | Minimum Clinically Important Improvement and Patient Acceptable Symptom State in Pain and Function in Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Back Pain, Hand Osteoarthritis, and Hip and Knee Osteoarthritis: Results From a Prospective Multinational Study |
| 001620 (2009) |
K. Visser [Pays-Bas] ; W. Katchamart [Canada] ; E. Loza [Espagne] ; J A Martinez-Lopez [Espagne] ; C. Salliot [France] ; J. Trudeau [Canada] ; C. Bombardier [Canada] ; L. Carmona [Espagne] ; D. Van Der Heijde [Pays-Bas] ; J W J. Bijlsma [Pays-Bas] ; D T Boumpas [Grèce] ; H. Canhao [Portugal] ; C J Edwards [Royaume-Uni] ; V. Hamuryudan [Turquie] ; T K Kvien [Norvège] ; B F Leeb [Autriche] ; E M Martín-Mola [Espagne] ; H. Mielants [Belgique] ; U. Müller-Ladner [Allemagne] ; G. Murphy [Irlande (pays)] ; M. Stergaard [Danemark] ; I A Pereira [Brésil] ; C. Ramos-Remus [Mexique] ; G. Valentini [Italie] ; J. Zochling [Australie] ; M. Dougados [France] | Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative |
| 001953 (2006) |
T. Pham [France] ; R. Landewé [Pays-Bas] ; S. Van Der Linden [Pays-Bas] ; M. Dougados [France] ; J. Sieper [Allemagne] ; J. Braun [Allemagne] ; J. Davis [États-Unis] ; M. Rudwaleit [Allemagne] ; E. Collantes [Espagne] ; R. Burgos-Vargas [Mexique] ; J. Edmonds [Australie] ; I. Olivieri [Italie] ; I. Van Der Horst-Bruinsma [Pays-Bas] ; H. Mielants [Belgique] ; M. Stone [Canada] ; P. Emery [Royaume-Uni] ; D. Van Der Heijde [Pays-Bas] | An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis |
| 001954 (2006) |
J. Zochling [Australie] ; D. Van Der Heijde [Pays-Bas] ; R. Burgos-Vargas [Mexique] ; E. Collantes [Espagne] ; J C Davis [États-Unis] ; B. Dijkmans [Pays-Bas] ; M. Dougados [France] ; P. Géher [Hongrie] ; R D Inman [Canada] ; M A Khan [États-Unis] ; T K Kvien [Norvège] ; M. Leirisalo-Repo [Finlande] ; I. Olivieri [Italie] ; K. Pavelka [République tchèque] ; J. Sieper [Allemagne] ; G. Stucki [Allemagne] ; R D Sturrock [Royaume-Uni] ; S. Van Der Linden [Pays-Bas] ; D. Wendling [France] ; H. Böhm [Allemagne] ; B J Van Royen [Pays-Bas] ; J. Braun [Allemagne] | ASAS/EULAR recommendations for the management of ankylosing spondylitis |
| 001A39 (2005) |
F. Tubach [France] ; P. Ravaud [France] ; G. Baron [France] ; B. Falissard [France] ; I. Logeart [France] ; N. Bellamy [Australie] ; C. Bombardier [Canada] ; D. Felson [États-Unis] ; M. Hochberg [États-Unis] ; D. Van Der Heijde [Pays-Bas] ; M. Dougados [France] | Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement |
| 001A90 (2004) |
L B A. Van De Putte [Pays-Bas] ; C. Atkins [Canada] ; M. Malaise [Belgique] ; J. Sany [France] ; A S Russell [Canada] ; P L C M. Van Riel [Pays-Bas] ; L. Settas [Grèce] ; J W Bijlsma [Pays-Bas] ; S. Todesco [Italie] ; M. Dougados [France] ; P. Nash [Australie] ; P. Emery [Royaume-Uni] ; N. Walter [Allemagne] ; M. Kaul [Allemagne] ; S. Fischkoff [États-Unis] ; H. Kupper [Allemagne] | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed |
| 001B19 (2004) |
L. B. A. Van De Putte [Pays-Bas] ; C. Atkins ; M. Malaise [Belgique] ; J. Sany [France] ; A. S. Russell [Canada] ; P. L. C. M. Van Riel [Pays-Bas] ; L. Settas [Grèce] ; J. W. Bijlsma [Pays-Bas] ; S. Todesco [Italie] ; M. Dougados [France] ; P. Nash [Australie] ; P. Emery [Royaume-Uni] ; N. Walter [Allemagne] ; M. Kaul [Allemagne] ; S. Fischkoff [États-Unis] ; H. Kupper [Allemagne] | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti rheumatic drug treatment has failed |
| 001D44 (1997) |
N. Bellamy [Canada, Royaume-Uni, Pays-Bas, Australie, États-Unis, France] ; J. Kirwan ; M. Boers ; P. Brooks ; V. Strand ; P. Tugwell ; R. Altman ; K. Brandt ; M. Dougados ; M. Lequesne | Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 6 | Rheumatoid arthritis |
| 6 | Rheumatology |
| 5 | Arthritis rheum |
| 4 | Chronic |
| 4 | Human |
| 4 | Rheum |
| 3 | American college |
| 3 | Ankylosing spondylitis |
| 3 | Antirheumatic drugs |
| 3 | Arthritis |
| 3 | Disease activity |
| 3 | Erythrocyte sedimentation rate |
| 3 | Expert opinion |
| 3 | Hip |
| 3 | Knee |
| 3 | Methotrexate |
| 3 | Monoclonal antibody |
| 3 | Nsaid |
| 3 | Osteoarthritis |
| 3 | Rheumatoid |
| 3 | TNF, tumour necrosis factor |
| 3 | Toxicity |
| 3 | Tumour necrosis factor |
| 2 | Adalimumab |
| 2 | Ankylosing |
| 2 | Asas |
| 2 | Asas recommendations |
| 2 | Baseline |
| 2 | Blocker |
| 2 | Braun |
| 2 | Clinical response |
| 2 | Clinical trials |
| 2 | Concomitant |
| 2 | DMARDs, disease modifying antirheumatic drugs |
| 2 | Dmard |
| 2 | Dmards |
| 2 | Effect size |
| 2 | Eular |
| 2 | Hand |
| 2 | Heijde |
| 2 | Improvement |
| 2 | Infliximab |
| 2 | Knee osteoarthritis |
| 2 | Lumbar spine |
| 2 | MRI, magnetic resonance imaging |
| 2 | Magnetic resonance imaging |
| 2 | Monotherapy |
| 2 | NSAID, non-steroidal anti-inflammatory drug |
| 2 | NSAIDs, non-steroidal anti-inflammatory drugs |
| 2 | Necrosis |
| 2 | OA, osteoarthritis |
| 2 | Randomised |
| 2 | Randomized |
| 2 | Reactive protein |
| 2 | Rheumatol |
| 2 | Rheumatologist |
| 2 | Side effects |
| 2 | Spondylitis |
| 2 | Symptomatology |
| 2 | Systematic review |
| 2 | Systemic lupus erythematosus |
| 2 | Treatment |
| 2 | VAS, visual analogue scale |
| 2 | Visual analogue scale |
| 1 | ACR, American College of Rheumatology |
| 1 | ANA, antinuclear antibody |
| 1 | AS, ankylosing spondylitis |
| 1 | ASAS |
| 1 | ASAS, ASsessment in AS |
| 1 | ASAS, ASsessment in Ankylosing Spondylitis |
| 1 | Abbott laboratories |
| 1 | Absolute change |
| 1 | Active ankylosing spondylitis |
| 1 | Active disease |
| 1 | Adalimumab monotherapy |
| 1 | Adalimumab treatment groups |
| 1 | Additional information |
| 1 | Adverse effects |
| 1 | Adverse event |
| 1 | Adverse events |
| 1 | Andersson lesion |
| 1 | Antibody infliximab |
| 1 | Antinuclear antibodies |
| 1 | Arthroplasty |
| 1 | Asas core |
| 1 | Atkins |
| 1 | Axial |
| 1 | Axial disease |
| 1 | BASDAI, Bath Ankylosing Spondylitis Disease Activity Index |
| 1 | Basdai |
| 1 | Basdai criterion |
| 1 | Basdai score |
| 1 | Basdai scores |
| 1 | Baseline characteristics |
| 1 | Baseline pain score |
| 1 | Baseline score |
| 1 | Baseline scores |
| 1 | Baseline value |
| 1 | Baseline visit |
| 1 | Bath ankylosing spondylitis |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "M. Dougados"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "M. Dougados" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= M. Dougados
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
